Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is -15.09% as of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
Limited quarterly history available
ROE needs at least three reported quarters before a meaningful chart is shown.
RETURN ON EQUITY (ROE)
-15.09%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+64.09%
vs the sector median at left
Aktis Oncology, Inc.
Market Cap
$952.79M
Return on Equity (ROE)
-15.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$957.40M
Return on Equity (ROE)
-96.97%
TTM Avg
-57.21%
3Y Avg
-47.20%
5Y Avg
-49.27%
Market Cap
$936.78M
Return on Equity (ROE)
N/A
TTM Avg
80.91%
3Y Avg
80.91%
5Y Avg
80.91%
Market Cap
$970.39M
Return on Equity (ROE)
2.18%
TTM Avg
-5.89%
3Y Avg
-1.23%
5Y Avg
4.05%
Market Cap
$978.27M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$925.92M
Return on Equity (ROE)
-612.78%
TTM Avg
-101.05%
3Y Avg
-68.21%
5Y Avg
-52.21%
Market Cap
$981.32M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$923.17M
Return on Equity (ROE)
-61.58%
TTM Avg
-50.64%
3Y Avg
-52.69%
5Y Avg
41.64%
Market Cap
$986.21M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $952.79M | -15.09% | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $957.40M | -96.97% | -57.21% | -47.20% | -49.27% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $936.78M | N/A | 80.91% | 80.91% | 80.91% |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.39M | 2.18% | -5.89% | -1.23% | 4.05% |
| MeiraGTx Holdings plc (MGTX)vs › | $978.27M | 36.64% | 876.73% | 395.64% | 252.56% |
| Kura Oncology, Inc. (KURA)vs › | $925.92M | -612.78% | -101.05% | -68.21% | -52.21% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $981.32M | -25.78% | 29.18% | 31.59% | 31.59% |
| MoonLake Immunotherapeutics (MLTX)vs › | $923.17M | -61.58% | -50.64% | -52.69% | 41.64% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $921.51M | -51.43% | -27.77% | 3.43% | 3.43% |
ROE
-15.1%
ROA
-13.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -15.09% |
